Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Alnylam Pharma (0HD2) Share Price & Analysis
3 Followers
0HD2 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$142.05 - $263.50
Previous Close$233.68
Volume918.00
Average Volume (3M)775.00
Market Cap
$29.71B
Enterprise Value$28.64B
Total Cash (Recent Filing)$2.37B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 01, 2024EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding126,491,778
10 Day Avg. Volume45
30 Day Avg. Volume775
Standard Deviation0.15
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-94.99
Price to Sales (P/S)43.11
Price to Cash Flow (P/CF)-175.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.39
Enterprise Value/Gross Profit18.87
Enterprise Value/Ebitda-221.21
Forecast
1Y Price Target
$268.95Price Target Upside15.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsHighly positive HELIOS-B topline results for Amvuttra in ATTR-CM with statistically significant improvements across all key secondary endpoints.
Financial PerformanceIn 2023, direct product sales by Alnylam of its 4 RNAi therapeutics crossed the billion dollar mark ($1.24 bn, +39%).
Market PotentialA convincing multi-billion dollar opportunity for Amvuttra in this setting.
Bears Say
Drug PricingUnclear rationale for a drug 2x the price with 80% of patients untreated and tafamidis genericization looming.
Market PenetrationThe high cost of VYNDAQEL has limited its penetration in Europe where it was first approved in 2011.
Stock ValuationWith ALNY shares pricing in a blue-sky scenario, risk/reward into ESC is skewed sharply to the downside.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
5.44% Other Institutional Investors
94.56% Public Companies and
Individual Investors
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $142.05 and its highest was $263.50 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 5 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$1.116 by $0.596.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.05.
How many shares outstanding does Alnylam Pharmaceuticals have?
Currently, no data Available
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.52 in its last earnings report, beating expectations of -$1.116. Following the earnings report the stock price went up 4.643%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 570M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$268.95 (15.09% Upside)
$268.95 (15.09% Upside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.75%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
0HD2 Company Deck
---
0HD2 Earnings Call
Q1 2024
0:00 / 0:00
---
0HD2 Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
0HD2 Stock 12 Month Forecast
Average Price Target
$268.95
▲(15.09% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Moderna
―
Bluebird Bio
―
Sangamo Biosciences
―
Best Analysts Covering 0HD2
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+25.05%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +25.05% per trade.
---